Sorry!! The article you are trying to read is not available now.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Eli Lilly (NY: LLY)
107.27 USD  +0.48 (+0.45%)
Official Closing Price  /  Updated: 7:08 PM EDT, Jul 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,894,500
Open 106.92
Bid (Size) 105.87 (1)
Ask (Size) 107.64 (1)
Prev. Close 106.79
Today's Range 105.87 - 107.36
52wk Range 88.17 - 132.13
Shares Outstanding 1,085,430,420
Dividend Yield 2.10%
Performance
YTD
-6.62%
-6.62%
1 Month
-7.23%
-7.23%
3 Month
-7.10%
-7.10%
6 Month
-8.39%
-8.39%
1 Year
+20.69%
+20.69%
Featured News
More News
Allergan acquisition is ‘a major bailout’ for shareholders, according to analysts
Shares of Allergan Plc soared Tuesday after news broke that the company was being acquired by pharmaceutical giant AbbVie Inc. in a deal worth around $63 billion. Read More
category M&A , TEVA , Company Announcements , and 16 more.
from MarketWatch
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion. Read More
category XBI , Health/Care , Pharmaceuticals , and 19 more.
from MarketWatch
Featured News
Read More
Drugmakers file lawsuit to block rule requiring drug prices in TV ads
category LLY , Biotechnology , AMGN , and 2 more.
from MarketWatch
Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s
category NVO , Biotechnology , ABBV , and 23 more.
from MarketWatch
The costs of brand-name prescription drugs double every 7 to 8 years, JAMA study finds
category PFE , LLY , General , and 4 more.
from MarketWatch
Pfizer, Eli Lilly, Bristol-Myer and J&J initiated with buy ratings by Goldman Sachs
category Medical Products , GILD , Biotechnology , and 14 more.
from MarketWatch
Pro-choice groups lost in Alabama despite outspending the pro-life side by 100-to-1
category General , WMT , PFE , and 6 more.
from MarketWatch
Will drug prices in TV ads really be transparent?
category LLY , Insurance , General , and 7 more.
from MarketWatch
More News
Read More
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
from GlobeNewswire News Releases
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
from PR Newswire
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
from PR Newswire
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migrai
from PR Newswire
111 Building "Fourth Sales Channel" to Support Pharmaceutical Companies and Accelerate Drug Distribution Outside of Hospitals
from PR Newswire
Noteworthy Friday Option Activity: LLY, ZS, FCX
category Stocks
from Market News Video
IWV, LLY, BKNG, MDLZ: Large Outflows Detected at ETF
category ETFs
from ETF Channel
Week In Review: How Trump's Policies Moved Stocks - July 21, 2019
from Blogs - TalkMarkets
Jim Cramer Weighs In On Marvell, General Motors And More
category Jim Cramer , Trading Ideas , GM , and 13 more.
from Benzinga
8 More Big Pharma Events in 2019 You Don't Want to Miss
category NVS , RHHBY , LLY , and 11 more.
from Motley Fool
RPT-BUZZ-U.S. stocks weekly: On a high
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

WHAT'S POPULAR IN THE VILLE